Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners Announce Collaboration to Launch Hillevax, Inc. to Develop Clinical Stage Norovirus Vaccine Candidate

07/29/2021 | 08:30am EDT

Takeda Pharmaceutical Company Limited and Frazier Healthcare Partners (Frazier) announced a collaboration to launch HilleVax Inc. (HilleVax), a biopharmaceutical company to develop and commercialize Takeda’s norovirus vaccine candidate. Takeda has granted a license to HilleVax for the exclusive development and commercialization rights to its norovirus vaccine candidate, HIL-214 (formerly TAK-214), worldwide outside of Japan, in exchange for upfront consideration, as well as future cash milestones and royalties on net sales. Takeda will retain commercialization rights in Japan and HilleVax will integrate certain Japan development activities into its global development. Takeda remains committed to vaccines, and this collaboration allows Takeda to focus its global resources on dengue, COVID-19, pandemic influenza and Zika, in addition to the vaccines it currently distributes in Japan. HIL-214, which is a virus-like particle (VLP) based vaccine candidate, completed a randomized, placebo-controlled Phase 2b field efficacy study in 4,712 adult subjects in which HIL-214 was well-tolerated and demonstrated clinical proof of concept in preventing moderate-to-severe cases of acute gastroenteritis from norovirus infection.1 To date, the candidate has been studied in nine human clinical trials with safety data from over 4,500 subjects and immunogenicity data from over 2,000 subjects. Norovirus is a common intestinal infection marked by diarrhea, vomiting, abdominal cramps, nausea and sometimes fever that may lead to clinically significant dehydration.2 Norovirus is recognized as the leading cause of acute gastroenteritis across the age spectrum.3 It is estimated that norovirus causes nearly 700 million cases of illness and more than 200,000 deaths worldwide per year with significant additional economic and social burden.3 No vaccines are currently approved for norovirus infection, and HIL-214 continues to be the most advanced norovirus vaccine candidate in human clinical trials.


© S&P Capital IQ 2021
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
09/27TAKEDA PHARMACEUTICAL : Obtains Regulatory Approval to Manufacture, Market Alofisel in Jap..
MT
09/27TAKEDA PHARMACEUTICAL : Receives Approval to Manufacture and Market Alofisel®▼ (darv..
PU
09/23Takeda Pharmaceutical Commences Construction on Zero-Emissions Building in Singapore fo..
MT
09/23TAKEDA PHARMACEUTICAL : WFP and Takeda deepen partnership in West Africa to strengthen hea..
AQ
09/23Navicon acquired Product Portfolio from Takeda Pharmaceutical Company Limited.
CI
09/22TAKEDA PHARMACEUTICAL : Breaks Ground on its First Zero Energy Building in Singapore
PU
09/22TAKEDA PHARMACEUTICAL : WFP and Takeda deepen partnership in West Africa to strengthen hea..
AQ
09/22TAKEDA PHARMACEUTICAL : Selects Four New Partners for Annual Global Corporate Social Respo..
BU
09/21MIRUM PHARMACEUTICALS : Partners With Takeda Over Developing, Commercializing Liver Diseas..
MT
09/21TAKEDA PHARMACEUTICAL : Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Ag..
BU
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 387 B 30 422 M 30 422 M
Net income 2022 253 B 2 276 M 2 276 M
Net Debt 2022 3 472 B 31 193 M 31 193 M
P/E ratio 2022 23,6x
Yield 2022 4,77%
Capitalization 5 930 B 53 442 M 53 269 M
EV / Sales 2022 2,78x
EV / Sales 2023 2,64x
Nbr of Employees 47 099
Free-Float 99,3%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 771,00 JPY
Average target price 4 844,67 JPY
Spread / Average Target 28,5%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED0.43%53 442
JOHNSON & JOHNSON3.68%429 542
ROCHE HOLDING AG9.24%319 352
PFIZER, INC.19.37%244 283
NOVO NORDISK A/S48.08%227 557
ELI LILLY AND COMPANY34.09%205 250